An update from Noxopharm Ltd. ( (AU:NOX) ) is now available.
Noxopharm Limited has announced an expansion of its collaboration with the Hudson Institute of Medical Research, aiming to advance its Sofra™ platform. This expansion will focus on exploring new targets in inflammation sensors and advancing cancer research, with the upcoming HERACLES trial marking a significant milestone. The partnership is based on a breakthrough discovery that explains the role of RNA fragments in autoimmune diseases, which underpins the development of new drugs to restore immune system balance. This development positions Noxopharm as a leading player in the growing RNA market, potentially impacting its industry positioning and offering new commercial opportunities.
More about Noxopharm Ltd.
Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company employs its proprietary technology platforms, Chroma™ for oncology and Sofra™ for inflammation, autoimmunity, and mRNA vaccine enhancement. Noxopharm collaborates with leading researchers and holds a significant shareholding in Nyrada Inc, a company specializing in novel small molecule therapies.
YTD Price Performance: -3.33%
Average Trading Volume: 114,130
Technical Sentiment Signal: Buy
Current Market Cap: A$24.84M
For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.